Clinical Trial Update: Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating low-dose inotuzumab ozogamicin after transplant to prevent relapse in patients with acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Lymphoid Leukemia | Phase 2 | Status: RECRUITING